Table 1 Participant characteristics
Characteristics | Participants (n = 24) |
|---|---|
Age (years, median [interquartile range]) | 64 (57–70) |
Sex, n (%) | |
Male | 20 (83) |
Female | 4 (17) |
Pathological types, n (%) | |
Lung squamous cell carcinoma | 9 (38) |
Lung adenocarcinoma | 5 (21) |
Lung neuroendocrine carcinoma | 2 (8) |
Small-cell lung cancer | 1 (4) |
Pulmonary sarcomatoid carcinoma | 1 (4) |
Thymic carcinoma | 1 (4) |
Rectal melanoma | 1 (4) |
Primary pulmonary melanoma | 1 (4) |
Lymphoma | 3 (13) |
Treatment, n (%) | |
Immune checkpoint blockade alone | |
Duvalumab | 1 (4) |
Immune checkpoint blockade combination with chemotherapy | |
Paclitaxel + carboplatin + pembrolizumab | 4 (17) |
Paclitaxel + carboplatin + tislelizumab | 5 (21) |
Paclitaxel + carboplatin + toripril | 3 (13) |
Paclitaxel + carboplatin + sintilimab | 1 (4) |
Pemetrexed + carboplatin + pembrolizumab | 2 (8) |
Pemetrexed + carboplatin + nivolumab | 1 (4) |
Etoposide + cisplatin + duvalumab | 1 (4) |
Etoposide + cisplatin + sintilimab | 1 (4) |
Nedaplatin + gemcitabine + suglizumab | 1 (4) |
Axitinib + toripril | 1 (4) |
CAR-T cell therapy | 3 (13) |
